In this article, we will list the 5 Best Buy-the-Dip Stocks to Invest In Now. Please visit 12 Best Buy-the-Dip Stocks to Invest In Now if you’d like to see an extended list and the methodology behind it.

5. Hamilton Lane Inc. (NASDAQ:HLNE)

Hamilton Lane Inc. (NASDAQ:HLNE) is one of the 12 best buy-the-dip stocks to invest in now.

On May 22, Oppenheimer updated its outlook on Hamilton Lane Inc. (NASDAQ:HLNE) after reviewing the company’s fourth-quarter numbers and noting that its year-to-date performance dropped more than the S&P’s 8.5%. The firm maintained its Outperform rating on the shares and adjusted the price target from $171 to $179. This comes after the company continued to report an unbroken string of strong quarters.

Oppenheimer also highlighted that because of clean operational results, minor margin improvements, and over 21% growth in management fees, the company saw more than 23% year-over-year jump in non-GAAP EPS. The reported figures of $1.49 for non-GAAP EPS exceeded the consensus estimates of $1.43. The firm noted that clients were putting more capital into higher fee funds, which will continue to lift revenues over time. This makes it a notable mention in recent Hamilton Lane stock analysis.

On May 22, Brennan Hawken from BMO Capital decreased the target price for Hamilton Lane Inc. (NASDAQ:HLNE) from $108 to $102. The analyst upheld an Outperform rating on the shares, which still yields more than 23% upside despite the price target revision.

Hawken highlighted that Hamilton Lane’s fourth-quarter fee-related earnings surpassed expectations, driven by lower compensation expenses and higher performance revenue.

Hamilton Lane Inc. (NASDAQ:HLNE) specializes in investments in businesses across different lifecycle stages. These include early-stage startups, mature or distressed companies, and more. With a preference for controlling stake, it focuses on tech-enabled companies across unique segments such as healthcare, energy, real estate, and industrials.

4. Wix.com Ltd. (NASDAQ:WIX)

Wix.com Ltd. (NASDAQ:WIX) is one of the 12 best buy-the-dip stocks to invest in now.

On June 2, Wix.com Ltd. (NASDAQ:WIX) was named an official web-building plugin partner for the launch of OpenAI’s Codex Enterprise. This integration directly links OpenAI’s agentic platform with Wix Headless, empowering users to transition from a conceptual business idea to a live, revenue-generating operation entirely within Codex.

The generated interfaces by Codex can be easily plugged into the backend services offered by Wix, using the plugin. It enables the launch of a live website that entails a customized domain, a fully configured CRM, and an active payments framework, all with only one command.

This functionality is enabled by the integration of Wix Headless and its Model Context Protocol (MCP), which sets up an important compliance and security framework for real-world AI agents. Wix manages data rules like GDPR and PCI-DSS natively at the infrastructure level, taking on the underlying operational and legal concerns.

Shahar Talmi, GM of Developer Platform at Wix, emphasized that this infrastructure ensures AI-generated storefronts can operate as fully functional and sustainable businesses at scale. Ultimately, this seamless integration eliminates the need for developers and entrepreneurs to manually stitch together disparate SaaS tools.

Wix.com Ltd. (NASDAQ:WIX) is a cloud-based web development platform that allows registered users to manage and grow their online businesses through AI-enabled tools. The company offers various services such as Wix Editor, Wix Studio Velo by Wix, Wix App Market, Wix Marketplace, and more.

3. Charter Communications Inc. (NASDAQ:CHTR)

Charter Communications Inc. (NASDAQ:CHTR) is one of the 12 best buy-the-dip stocks to invest in now.

On June 5, Charter Communications Inc.’s (NASDAQ:CHTR) Spectrum brand made the announcement to expand its extensive network of fiber broadband. This will allow the company to deliver its Voice, TV, Mobile, and Internet offerings across areas that had been unserved or were minimally served. This entails 840+ additional residential and commercial customers.

The company’s Kentucky Management Area Vice President, Heather Day, reflected on the company’s multi-year ambition covering the rural sites. He attributed such ambition to massive private investment worth roughly $7 billion by the management. It clearly indicates a strong commitment towards a fiber infrastructure that would include more than 100,000 miles of additional capacity. Moreover, the management is confident about serving 1.7 million additional locations within the country, at highly efficient multi-gigabit speeds. Day stated:

“Spectrum is bringing gigabit broadband to rural communities in Indiana and across America. Our investment is providing residents and small businesses superior connectivity at highly competitive prices, backed by a team of skilled local technicians and 100% U.S.-based customer service.”

Charter Communications Inc. (NASDAQ:CHTR) is a broadband connectivity company. Under the Spectrum brand umbrella, it delivers voice, mobile, internet, and video services. It offers data networking solutions to business entities, while also delivering cable TV, video on demand, and advertising services. The company also owns local news channels, regional sports networks, and extends broadband connectivity to apartments, student housing, and RV parks.

2. Summit Therapeutics Inc. (NASDAQ:SMMT)

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 12 best buy-the-dip stocks to invest in now.

On June 10, an underwritten public offering of common stock valued at $500 million was initiated by Summit Therapeutics Inc. (NASDAQ:SMMT). The company stated in its announcement that 100% of the shares in this proposed transaction are being offered directly by Summit. To manage and coordinate the equity issuance process, the firm has appointed J.P. Morgan, Goldman Sachs & Co., and Citigroup to serve as the joint book-running managers.

On June 1, following the presentation of Phase 3 HARMONi-6 trial data at an ASCO plenary session, Cantor Fitzgerald reaffirmed its Overweight rating on Summit Therapeutics Inc. (NASDAQ:SMMT). As a first-line treatment for squamous non-small cell lung cancer (NSCLC), the China-based research evaluated the combination of ivonescimab and chemotherapy versus tislelizumab plus chemotherapy.

The ivonescimab combination produced a median progression-free survival (PFS) of 11 months and a hazard ratio of 0.60, according to previously published results at ESMO 2025. Overall survival (OS) data were still in their infancy at the time. Cantor pointed out that worries about whether PFS enhancements will eventually result in an OS benefit in the first-line scenario are addressed by the interim OS data from HARMONi-6.

The main question at hand is whether the Phase 3 HARMONi-3 trial, which is comparing ivonescimab with chemotherapy versus pembrolizumab plus chemotherapy in first-line NSCLC, can repeat these favorable results worldwide. The second part of 2026 is when results are expected. Although the speaker acknowledged that HARMONi-6 showed efficacy in China, concerns were raised during the ASCO discussion about the regimen’s suitability for patients in the United States.

Summit Therapeutics Inc. (NASDAQ:SMMT) is a clinical-stage biopharma company that develops and commercializes medical oncology therapies. It is focused on developing ivonescimab, a bispecific antibody that combines blockade of PD-1 and anti-angiogenesis in a single molecule. It is also running Phase III clinical trials for the treatment of non-small lung cancer.

1. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 12 best buy-the-dip stocks to invest in now.

As of June 5 closing, the consensus sentiment around Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) remained strongly bullish. Based on a median one-year target price of $51.87, the stock offers more than 122% upside.

Back on May 21, Kristen Kluska from Cantor Fitzgerald increased the target price for the stock from $84 to $96, resulting in a revised upside potential of almost 312%. The analyst reiterated her Overweight rating on the stock, based on a greater statistical success probability of GTX-102 to cure Angelman syndrome. This stems from the Phase 3 design, enabling the threshold for statistical significance to be compartmentalized into 2 endpoints, i.e., MDRI and Bayley-4 cognitive raw score.

More recently, the U.S. Food and Drug Administration issued draft guidance designed to streamline the development and regulatory submission process for promising human gene therapies. After it is finalized, the framework will describe how developers can use current scientific data, public information, and established platform expertise. These include manufacturing, chemistry, and control data, as well as nonclinical and clinical outcomes.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), being a key player in this space, is expected to benefit from this development. This regulatory effectiveness focuses on gene therapy products that use genome editing in human somatic cells.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) develops novel therapies, with a focus on identifying, acquiring, and commercializing products for rare and ultra-rare genetic diseases. It has a strong emphasis on gene therapy and covers various stages of clinical trials. The company is currently going through high cash burn with the aim of turning profitable from 2027 onwards.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.